This is some text inside of a div block.

How to measure the ROI of a weight loss benefit

Nicholas Syhler

November 6, 2026

min read

Last updated October 2026 · 6 min read

TL;DR

In a Prime Therapeutics claims analysis, members on GLP-1s for weight loss cost $6,994 more than matched controls in year one and $4,206 more in year two, with no significant medical cost offsets [1].
Obesity costs employers an estimated $6,472 a year per employee with obesity, mostly in absence, presenteeism and medical costs [2], so the cost of doing nothing is real.
Judge ROI on a two to three year horizon and on cost per engaged member, dose, persistence and weight maintained, not on enrollment.
Ask every vendor for member-level outcomes at fixed timepoints, average dose, time on medication and offboarding results before you sign.

What does ROI mean for a weight loss benefit?

ROI for a weight loss benefit is the change in total cost and workforce value it produces, divided by what you spend on it. That spans three ledgers, and most employers only look at the first.

Pharmacy: GLP-1 spend, dose per member and months on therapy. Among employers covering weight-loss GLP-1s, these drugs averaged 11.4% of total claims in 2025 [3].
Medical: claims tied to type 2 diabetes, hypertension, sleep apnea, joint pain and cardiovascular events.
Workforce: absence, presenteeism, disability and retention. In a 2024 study, presenteeism and absenteeism made up a larger share of employers' obesity costs than excess medical spend [2].

Our guide to cost-effective GLP-1 coverage covers how to design the benefit. This post covers how to prove it works.

Do GLP-1s pay for themselves?

Not within two years on medical claims alone, based on the best real-world data available. The Prime Therapeutics analysis of 3,046 GLP-1 users and 8,653 matched controls found higher total cost of care in both years and no significant medical offsets [1].

Over a lifetime the picture changes. ICER's December 2025 report called semaglutide and tirzepatide highly cost-effective at current net prices of $6,829 and $7,973 [4]. But that is a health system view; median tenure with a current employer is 4.1 years [5], so much of the long-term value lands after an employee has left.

Why persistence breaks the math

Only 1 in 12 people who start a GLP-1 for obesity are still on it three years later [6]. In STEP 1, participants regained two-thirds of their lost weight within a year of stopping [7]. Spend on members who stop and regain produces little lasting return, which is why offboarding is an ROI issue, not just a clinical one. See weight regain after stopping GLP-1s.

Which metrics should you track?

Track a small set of metrics that link spend to lasting outcomes, and report them per engaged member. Enrollment and app logins are activity, not ROI.

Cost metrics

Total program cost per engaged member per month, medication included
Average GLP-1 dose per member and the share on maximum dose
Months on medication and the share who taper or stop with support

Outcome metrics

Average percent weight loss at fixed timepoints, with the number of members still measured at each
Share reaching at least 5% and 10% weight loss
Weight maintained six months after tapering or stopping
Changes in blood pressure, HbA1c and lipids where available

Workforce metrics

Absence days and short-term disability claims, compared with a matched group
Member satisfaction and retention among participants

Case study: over 70% lower GLP-1 costs in ten months. One self-funded employer kept GLP-1 access open, cut GLP-1 costs by over 70% and broke even in year one. Download the case study

What time horizon should you use?

Use two to three years for the business case and expect each ledger to move at a different speed. Agree this with finance before launch, so year-one results are not judged against a five-year promise.

Months 0 to 12: pharmacy cost per member, dose and engagement. This is where coverage design shows up first.
Years 2 to 3: persistence, weight maintained after tapering and early movement in comorbidity markers.
Years 3 to 5: medical claims. Dall et al. modeled five-year medical savings at the industry level of $153.3 billion with 5% weight loss and $326.1 billion with 25% weight loss [2], which shows the size of the prize and how long it takes.

How do you build a simple ROI model?

Build the model per engaged member, not per employee, and keep every input visible. A transparent model you can update quarterly beats a vendor's single headline number.

Baseline: current weight-loss GLP-1 spend per user and the number of users.
Program cost: fee per engaged member, plus any medication billed separately.
Pharmacy change: projected dose and months on therapy under the new design versus today.
Medical change: use conservative assumptions, and set them to zero for year one, in line with the Prime data [1].
Workforce value: include it as a separate line, not inside the payback figure.
Sensitivity: rerun with persistence and engagement 25% lower than the vendor assumes.

For cost inputs, see how much GLP-1s cost self-funded employers, or try the Embla savings calculator.

What data should you ask vendors for?

Ask for data that would let you rebuild their ROI claim yourself. If a vendor cannot provide it, treat the claim as marketing.

Published or peer-reviewed outcomes, with the number of participants measured at each timepoint
Average medication dose and how it compares with the standard maximum
Share of members who taper or stop medication, and their weight afterwards
Monthly reporting on engaged members, dose and outcomes for your population
A pricing model where you pay only for engaged members

More questions are in how to evaluate a weight loss vendor.

How does Embla report on ROI?

Embla is built so the cost drivers above are visible and move in the right direction. Members work with coaches first, and independent licensed clinicians prescribe GLP-1s where appropriate, using a low-dose, treat-to-target protocol with structured tapering from month 16. Employers pay a fixed fee per engaged member that includes medication, so Embla carries the medication risk.

In the TRIM study, Embla's own published research in 2,694 participants, average weight loss was 16.7% over 64 weeks at an average dose of about 1.08 mg/week, less than half the standard maximum dose [8]. In one self-funded employer over ten months, GLP-1 costs were over 70% lower, with break-even in year one (read the case study). See Embla results.

Checklist: before you sign off a weight loss benefit

Agree a two to three year ROI horizon with finance and HR.
Set baseline GLP-1 spend, users and dose from the last 24 months of claims.
Choose five to eight metrics from the lists above and fix the reporting cadence.
Require member-level outcome and dose data in the contract.
Model payback with medical offsets at zero for year one.
Review results quarterly and rerun the model at renewal.

Frequently asked questions

What is a realistic ROI timeline for GLP-1 coverage?

Expect pharmacy savings from a well-designed program within year one, and medical savings over three to five years. Real-world claims data found no medical offsets within two years for medication-only coverage [1].

Should productivity count toward ROI?

Yes, but report it separately. Absence and presenteeism are a large part of what obesity costs employers [2], yet they are harder to measure than claims, so keep them out of the core payback figure.

How do we compare vendors' ROI claims?

Ask for the inputs behind the number: population, timepoints, dose, persistence and who funded the analysis. Then plug them into your own model.

Does covering fewer people improve ROI?

Tighter eligibility lowers spend, but not necessarily ROI per member. Dose, duration and offboarding usually move ROI more than BMI thresholds alone.

References

Myshko D. Prime Therapeutics finds no medical cost offsets for GLP-1 obesity drugs (AMCP Annual 2025). Managed Healthcare Executive, 2025. Link
Dall TM, Sapra T, Natale Z, Livingston T, Chen F. Assessing the economic impact of obesity and overweight on employers: identifying opportunities to improve work force health and well-being. Nutrition & Diabetes, 2024. Link
Becker's Hospital Review. Employer coverage of GLP-1s for diabetes, weight loss remains steady at 36%: survey (reporting the International Foundation of Employee Benefit Plans GLP-1 pulse survey). Becker's, 2026. Link
Institute for Clinical and Economic Review. ICER publishes final evidence report on treatments for obesity. ICER, 2025. Link
U.S. Bureau of Labor Statistics. Employee tenure summary. BLS, 2026. Link
Prime Therapeutics. Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years. Prime Therapeutics, 2025. Link
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. Link
Seier S, Stamp-Larsen K, Jensen SBK, Torekov SS, Gudbergsen H. Treat to target in weight management with semaglutide: real-world evidence from an eHealth clinic (the TRIM study, Embla's own published research). Diabetes, Obesity and Metabolism, 2025. DOI 10.1111/dom.70096. Link